PE20230036A1 - Variantes de progranulina - Google Patents

Variantes de progranulina

Info

Publication number
PE20230036A1
PE20230036A1 PE2022001166A PE2022001166A PE20230036A1 PE 20230036 A1 PE20230036 A1 PE 20230036A1 PE 2022001166 A PE2022001166 A PE 2022001166A PE 2022001166 A PE2022001166 A PE 2022001166A PE 20230036 A1 PE20230036 A1 PE 20230036A1
Authority
PE
Peru
Prior art keywords
progranulin
variants
proteins
ftd
polypeptide
Prior art date
Application number
PE2022001166A
Other languages
English (en)
Inventor
Gerald Maxwell Cherf
Gunasekaran Kannan
Katrina W Lexa
Ray L Y Low
Rachel Prorok
Ankita Srivastava
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Priority claimed from PCT/US2020/066831 external-priority patent/WO2021133907A1/en
Publication of PE20230036A1 publication Critical patent/PE20230036A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Se proporcionan en la presente variantes de progranulina y proteinas de fusion que comprenden una variante de progranulina y un polipeptido Fc. Tambien se proporcionan en la presente metodos para el uso de dichas proteinas para el tratamiento de trastornos asociados con la progranulina (por ejemplo, una enfermedad neurodegenerativa, tal como demencia frontotemporal (FTD))
PE2022001166A 2019-12-23 2020-12-23 Variantes de progranulina PE20230036A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953099P 2019-12-23 2019-12-23
US202063091819P 2020-10-14 2020-10-14
PCT/US2020/066831 WO2021133907A1 (en) 2019-12-23 2020-12-23 Progranulin variants

Publications (1)

Publication Number Publication Date
PE20230036A1 true PE20230036A1 (es) 2023-01-10

Family

ID=76437806

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001166A PE20230036A1 (es) 2019-12-23 2020-12-23 Variantes de progranulina

Country Status (12)

Country Link
US (4) US20210188925A1 (es)
EP (1) EP4081536A1 (es)
JP (1) JP2023507846A (es)
KR (1) KR20220130678A (es)
CN (1) CN114981297A (es)
AU (1) AU2020411480B2 (es)
BR (1) BR112022012230A2 (es)
CA (1) CA3165846A1 (es)
CO (1) CO2022008648A2 (es)
IL (1) IL293994A (es)
MX (1) MX2022007486A (es)
PE (1) PE20230036A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
IL293994A (en) 2019-12-23 2022-08-01 Denali Therapeutics Inc Variants of progranulin, preparations containing them and their uses
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110938A1 (en) 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
US6743893B2 (en) 2000-11-30 2004-06-01 The Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
PT2279753E (pt) 2001-10-10 2016-01-15 Novo Nordisk As Remodelação e glicoconjugação de péptidos
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050123962A1 (en) 2003-10-28 2005-06-09 Agy Therapeutics, Inc. Regulated nucleic acids in pathogenesis of alzheimer's disease
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
DK2037948T3 (en) 2006-05-30 2016-08-01 Mayo Foundation Detection and treatment of dementia
WO2008019187A2 (en) 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia
LT2029742T (lt) 2006-06-07 2016-11-10 Genzyme Corporation Genų terapija, skirta amiotrofinei lateralinei sklerozei ir kitiems stuburo smegenų sutrikimams
US7928068B2 (en) 2007-01-31 2011-04-19 New York University Methods for using GEP, a chondrogenic growth factor and target in cartilage disorders
DE102007033359B4 (de) 2007-07-16 2010-12-02 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen
EP2249861B1 (en) 2008-01-16 2016-07-06 Neurodyn Life Sciences Inc. Progranulin for use in treating parkinson's disease or alzheimer's disease
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CA2758542A1 (en) 2009-04-17 2010-10-21 New York University Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
US20150352185A1 (en) 2010-11-16 2015-12-10 Denis G. Kay Method for increasing neprilysin expression and activity
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
RU2013140685A (ru) 2011-02-04 2015-03-10 Дженентек, Инк. ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2842969B1 (en) 2012-04-23 2018-03-14 NRL Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
KR20190121874A (ko) 2012-08-29 2019-10-28 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
AU2013352812B2 (en) 2012-11-27 2019-06-20 Ajou University Industry-Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
BR112015012014A2 (pt) 2012-12-04 2017-07-11 Abbvie Inc proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
CA3166758A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
PL3594240T3 (pl) 2013-05-20 2024-04-02 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
SG10201800982QA (en) 2013-07-05 2018-03-28 Genmab As Humanized or chimeric cd3 antibodies
UA116665C2 (uk) 2013-07-31 2018-04-25 Емджен Інк. Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)
WO2015024931A1 (en) 2013-08-19 2015-02-26 Moghimi Seyed Moien Peptidic nanodelivery composition targeting two receptors
CN106573153A (zh) 2014-02-04 2017-04-19 纽约大学 用于诊断和治疗溶酶体贮积病的颗粒蛋白前体(pgrn)及其衍生物
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
EP3218411B1 (en) 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
PT3221357T (pt) 2014-11-20 2020-07-28 Hoffmann La Roche Cadeias leves comuns e métodos de utilização
ES2908009T3 (es) 2015-06-24 2022-04-27 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad adaptada
EP3313890A1 (en) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
KR20180020277A (ko) 2015-06-24 2018-02-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
WO2017024137A1 (en) 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
AU2016323440B2 (en) 2015-09-15 2023-07-13 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2018013775A2 (en) 2016-07-14 2018-01-18 Emory University Granulin compositions and uses related thereto
IL266156B1 (en) 2016-12-26 2024-01-01 Japan Chem Res A new antibody against the human transferrin receptor, capable of penetrating the blood-brain barrier
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
CN111148757A (zh) 2017-08-10 2020-05-12 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
CN111741977A (zh) 2018-01-10 2020-10-02 戴纳立制药公司 转铁蛋白受体结合性多肽和其用途
WO2019203555A1 (ko) 2018-04-17 2019-10-24 한국생명공학연구원 Ｐｒｏｇｒａｎｕｌｉｎ 단백질을 포함하는 간질환의 예방 또는 치료용 조성물
BR112020025306A2 (pt) 2018-06-18 2021-03-09 Denali Therapeutics Inc. Proteínas de fusão compreendendo progranulina
JP7397063B2 (ja) 2018-08-16 2023-12-12 デナリ セラピューティクス インコーポレイテッド 操作された二重特異性タンパク質
WO2020041604A1 (en) 2018-08-22 2020-02-27 Denali Therapeutics Inc. Anti-her2 polypeptides and methods of use thereof
WO2020081575A1 (en) 2018-10-16 2020-04-23 Denali Therapeutics Inc. Methods for treating and monitoring progranulin-associated disorders
US20220025065A1 (en) 2018-12-10 2022-01-27 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
CA3134538A1 (en) 2019-04-03 2020-10-08 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
IL293994A (en) 2019-12-23 2022-08-01 Denali Therapeutics Inc Variants of progranulin, preparations containing them and their uses
KR20220131246A (ko) 2020-01-13 2022-09-27 데날리 테라퓨틱스 인크. 항-trem2 항체 및 이의 사용 방법
US20230092681A1 (en) 2020-02-07 2023-03-23 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
AU2021362487A1 (en) 2020-10-14 2023-06-08 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia

Also Published As

Publication number Publication date
CO2022008648A2 (es) 2022-06-30
IL293994A (en) 2022-08-01
JP2023507846A (ja) 2023-02-27
CN114981297A (zh) 2022-08-30
MX2022007486A (es) 2022-06-29
EP4081536A1 (en) 2022-11-02
AU2020411480B2 (en) 2023-12-21
US20230265137A1 (en) 2023-08-24
US20220213155A1 (en) 2022-07-07
US11643446B2 (en) 2023-05-09
BR112022012230A2 (pt) 2022-08-30
AU2020411480A1 (en) 2022-06-30
US20220220172A1 (en) 2022-07-14
US20210188925A1 (en) 2021-06-24
CA3165846A1 (en) 2021-07-01
KR20220130678A (ko) 2022-09-27

Similar Documents

Publication Publication Date Title
CL2020003255A1 (es) Proteínas de fusión que comprenden progranulina
PE20230036A1 (es) Variantes de progranulina
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
MX2020006322A (es) Proteinas de fusion il-2 fc modificadas.
CL2020000810A1 (es) Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas.
TWD217367S (zh) 護目鏡之部分
CR20190480A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
CL2022001712A1 (es) Variantes de progranulina
AR115565A1 (es) Proteínas de fusión que comprenden progranulina
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
EA202190062A1 (ru) Слитые белки, содержащие програнулин
CO2020013557A2 (es) Variantes de lfa3 y composiciones y usos de las mismas
AR119984A1 (es) Proteínas de fusión nkg2d y sus usos
CO2020008885A2 (es) Arilsulfatasa a purificada y composiciones de la misma
TWD166161S (zh) 眼鏡（四）
TWD168623S (zh) 眼鏡（五）
TWD168627S (zh) 眼鏡（九）
UA97336U (en) Glasses-transformers